Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
MicroPort CardioFlow Medtech Corp. ( (HK:2160) ) just unveiled an update.
MicroPort CardioFlow Medtech has entered into new 2026 international distribution framework agreements with its major shareholder MicroPort, allowing it to distribute certain cardiovascular and electrophysiology products in selected overseas regions, including Europe. The deals, running through the end of 2028, are classified as continuing connected transactions under Hong Kong listing rules, triggering reporting and review obligations but exempting the company from independent shareholder approval, and are expected to support its global expansion while remaining within prescribed related-party transaction thresholds.
The most recent analyst rating on (HK:2160) stock is a Sell with a HK$0.74 price target. To see the full list of analyst forecasts on MicroPort CardioFlow Medtech Corp. stock, see the HK:2160 Stock Forecast page.
More about MicroPort CardioFlow Medtech Corp.
MicroPort CardioFlow Medtech Corporation is a medical technology company specializing in cardiovascular devices, operating within the broader MicroPort group structure. The company focuses on distributing cardiovascular and electrophysiology products in overseas markets, including Europe, leveraging intra-group partnerships to expand its international footprint.
Average Trading Volume: 2,185,998
Technical Sentiment Signal: Sell
Current Market Cap: HK$3.69B
Find detailed analytics on 2160 stock on TipRanks’ Stock Analysis page.